Shire shares have taken a beating this year, but they got a boost Friday from third-quarter earnings results investors viewed favorably. More: Under breakup pressure, Shire cheers grumpy investors with Q3 earnings beat Source: fierce
read moreThe cyberattack that took out some of Merck & Co.’s manufacturing capabilities this summer continues to haunt the drugmaker, but it was able to beat the Street’s projections on earnings and raised its forecast to boot. More: Merck raises forecast
read moreLooming generic competition for AbbVie’s top-selling drug, Humira, threatens the top line while putting extreme pressure on the company to deliver follow-up blockbusters from its pipeline. Today the company took a big step toward putting investors’ minds at ease on
read moreDr. Reddy’s is recalling 569,000 heartburn tablets sold in the U.S. and continues to suffer from manufacturing issues at its plants, China has approved a domestically developed Ebola vaccine based on the 2014 outbreak virus type and more. More: FiercePharmaAsia—Dr.
read moreThe NHS could have prevented the WannaCry cyber attack earlier this year if it followed basic IT security best practice, an investigation by the National Audit Office has found. More: NHS could have prevented WannaCry attack Source: News
read moreEuropean regulators have approved a label extension for Shire’s Firazyr, broadening its use include adolescents and children aged two years and older with a particular type of HAE. More: Shire’s HAE drug Firazyr cleared for children Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals